News / Health

Ebola Emergency Turns Spotlight on Experimental Drugs

Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
Reuters

With hundreds of patients in Africa suffering the devastating effects of Ebola, health experts are scrambling to determine which drugs might offer the best experimental treatment, and researchers are being pressed by government officials to speed up their work.

Three treatments have shown especially promising results in monkeys, the researchers said. One, produced by tiny California biotech Mapp Biopharmaceutical, gained international prominence this week when it was given to two U.S. aid workers who contracted Ebola in West Africa and have since shown signs of improvement.

Others are from Vancouver-based Tekmira Pharmaceuticals and privately-held Profectus BioSciences, of Tarrytown, NY.

Click to enlargeClick to enlarge
x
Click to enlarge
Click to enlarge

On Wednesday the World Health Organization said it would discuss next week the ethics of using Ebola drugs that have never been cleared for human use, wary of a long history of medicines being tested on people who were never properly informed of the risks. In the countries hardest hit by Ebola, suspicion of foreign medical workers is already widespread.

But the health minister of Nigeria, Onyenbuchi Chukwu, told reporters this week that he had asked U.S. health officials about access to experimental Ebola therapies. U.S. drugmakers are fielding questions from government officials about their ability to supply treatments in sufficient quantities should the request come.

"For years we've told the government you need to invest a little bit of money in this," said Profectus chief scientific officer John Eldridge. "And now it's, 'Oh my God, how fast can you make this?' "

Officials at Mapp and Tekmira would not comment on efforts to make their treatments available in response to the outbreak.

President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
x
President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.

Speaking at a news conference on Wednesday, President Barack Obama said he lacks enough information to green-light Mapp's drug to treat the deadly Ebola virus and that the initial response should focus on public health measures to contain the outbreak.

"We've got to let the science guide us, and I don't think all the information is in on whether this drug is helpful," the president said, adding that public health officials, in the course of containing the current outbreak, could assess whether new drugs or treatments can be effective.

"We're focusing on the public health approach right now, but I will continue to seek information about what we're learning about these drugs going forward," he said.

Dr. James Crowe, director of the Vaccine Center at Vanderbilt University who has been developing an Ebola treatment similar to Mapp's, said a Pentagon agency contacted him this week about his work and added he will meet next week with government scientists about accelerating his research.

Monkey tests

No Ebola drugs or vaccines have even entered mid-stage human trials, let alone been approved. The furthest along have been tested only in monkeys and a handful of humans.

Mapp Biopharmaceutical began developing its ZMapp treatment more than a decade ago. It consists of a cocktail of nonoclonal antibodies, proteins that are highly specific for the Ebola virus and that are produced in bioengineered tobacco plants.

In 2012 Mapp, working with scientists at the U.S. Army Military Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland, announced that when rhesus macaques received the cocktail an hour after infection by Ebola, all survived. When they received it 48 hours after infection, two-thirds survived.

Last year, ZMapp passed a stiffer test: monkeys that had been infected with Ebola and developed fevers and other symptoms received the intravenous cocktail 104 to 120 hours after infection; 43 percent recovered.

When the U.S. government decided to develop a contingency plan in case of accidental exposure to Ebola by one or two people at a U.S. research facility, it began storing a small amount of ZMapp, according to a source familiar with the contingency plan. ZMapp was chosen because the science is relatively easy to understand and the risks considered relatively small, the source said.

The stock of Tekmira soared on expectations its Ebola drug might speed toward approval due to the crisis, or even be used in the current outbreak.

Under a $140 million contract with the U.S. Department of Defense, it is developing a drug based on a genetic technology called RNA interference.

The idea is to take strands of genetic material that are the virus's mirror image and, using nanoparticles, slip them into cells where Ebola is replicating. In theory, the RNA disables the virus.

In experiments by scientists at the army research unit, Tekmira reported last November, most animals infected with lethal amounts of Ebola survived when given the RNA product. The survival rate was 83 percent when the animals were treated 24 or 48 hours after infection and 67 percent when they were treated 72 hours after.

"It is amazing how well that works in non-human primates," said Ebola researcher Thomas Geisbert of the University of Texas Medical Branch, who has conducted several studies of the company's drug in monkeys.

Human trials

Last month, Tekmira announced that its early-stage human trial had been put on hold by the U.S. Food and Drug Administration, which had concerns about the drug's safety.

Tekmira declined requests for an interview.

Profectus BioSciences has also tested its Ebola vaccine in monkeys, with good results, said Eldridge.

In a study with scientists at government biomedical research centers and the Pentagon, Profectus found that a single intramuscular injection protected all of the rhesus monkeys exposed to Ebola three weeks later. The company hopes to launch a human trial to assess the vaccine's safety within the next 12 months, Eldridge said.

An experimental vaccine similar to Profectus's, developed by academic and government scientists, was rushed into emergency use only once. In 2009 a scientist in Germany working with Ebola-infected guinea pigs pricked her finger with a syringe containing the virus. The vaccine was flown from Canada, one of the sites where it was being developed.

"She got that vaccine in less than 40 hours and survived," said Geisbert, though it's impossible to know whether that was because of the vaccine. "She lived. That's all I care about."

With greater financial support, scientists said, Ebola treatments could be ready for use sooner. For less than $10 million, said Vanderbilt's Crowe, four or five of the experimental drugs could be ready for testing within in four months.

All of them seem to be effective only in a small window after exposure, however.

"Nothing on planet Earth is going to work if somebody comes in with full-blown Ebola hemorrhagic fever and they are 24 hours or 72 hours from death," said Geisbert. "The damage has been done."

You May Like

China’s Influence Grows With New Infrastructure Bank

Multibillion-dollar China-backed and BRICS-supported Asian Infrastructure Investment Bank seen as possible challenger to such lenders as IMF, World Bank More

Video Rabbi Hits Road to Heal Jewish-Muslim Relations in France

Rabbi Michel Serfaty makes the rounds in his friendship bus to encourage dialogue and break down barriers between the two groups More

Post-deal Iran Leaders Need 'Economic Momentum' to Solidify

Economists say deal could inject more than $100 billion into coffers - not enough to entirely rescue ailing economy - but maybe adequate to create 'economic momentum' More

This forum has been closed.
Comment Sorting
Comments
     
by: John
August 11, 2014 11:00 AM
The US is still involved in the war in Somalia, decades after Bush Snr foolishly sent troops to help distribute food to the starving. The revolt by Boko Haram against polio vaccination goes from strength to strength. (Don't know whether the suit against the drug company that tested an experimental drug on the people of Kano has been settled though.) Yet some people still think we should give experimental drugs to Africans. They'll never learn!! The fact is, if Africans were really concerned about this disease, they'd have made a deal with Western drug companies to do the clinical trials of potential vaccines and cures decades ago. This doesn't take super technical skill; merely careful record keeping and a plentiful supply of victims---oops brave volunteers, to try the drugs. They just decided to wait until we panicked, so we'd provide all the money and guinea pigs ourselves. Must admit their strategy is working like a charm!!!

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
US Gay Marriage Ruling Yields Real-life Impacti
X
Michael Bowman
June 28, 2015 10:05 PM
Friday’s landmark Supreme Court decision legalizing same-sex marriage throughout the United States is an outcome few thought possible just years ago, and shows a nation that increasingly tolerates and even celebrates the hopes and aspirations of gay people. VOA’s Michael Bowman spoke to a same-sex couple that will benefit from the high court ruling, and to a Christian scholar who is apprehensive about its potential consequences for America’s faith community.
Video

Video US Gay Marriage Ruling Yields Real-life Impact

Friday’s landmark Supreme Court decision legalizing same-sex marriage throughout the United States is an outcome few thought possible just years ago, and shows a nation that increasingly tolerates and even celebrates the hopes and aspirations of gay people. VOA’s Michael Bowman spoke to a same-sex couple that will benefit from the high court ruling, and to a Christian scholar who is apprehensive about its potential consequences for America’s faith community.
Video

Video Syrians Flee IS Advance in Hasaka

The Syrian government said Monday it has taken back one of several districts in Hasaka overrun by Islamic State militants. But continued fighting elsewhere in the northern city has forced thousands of civilians from their homes. In this report narrated by Bill Rodgers, VOA Kurdish Service reporter Zana Omer describes the scene in Amouda, where some of the displaced are taking refuge.
Video

Video Rabbi Hits Road to Heal Jewish-Muslim Relations in France

France is on high alert after last week's terrorist attack near the city Lyon, just six months after deadly Paris shootings. The attack have added new tensions to relations between French Jews and Muslims. France’s Jewish and Muslim communities also share a common heritage, though, and as far as one French rabbi is concerned, they are destined to be friends. From the Paris suburb of La Courneuve, Lisa Bryant reports about Rabbi Michel Serfaty and his friendship bus.
Video

Video S. Korea Christians Protest Gay Rights Festival

The U.S. Supreme Court decision mandating marriage equality nationwide has energized gay rights supporters around the world. Gay rights remain a highly contentious issue in a key U.S. ally, South Korea, where police did a deft job Sunday of preventing potential clashes between Christian protesters and gay activists. Kurt Achin reports from Seoul.
Video

Video Saudi Leaks Expose ‘Checkbook Diplomacy’ In Battle With Iran

Saudi Arabia’s willingness to wield its oil money on the global diplomatic stage appears to have been laid bare, after the website WikiLeaks published tens of thousands of leaked cables from Riyadh’s Ministry of Foreign Affairs. VOA's Henry Ridgwell reports.
Video

Video Nubians in Kenya Face Land Challenges

East Africa's ethnic Nubians have a rich cultural history that dates back thousands of years, but in Kenya they are facing hardships, including the loss of lands they have lived on for generations. They say the government has reneged on its pledge to award them title deeds for the plots. VOA's Lenny Ruvaga reports.
Video

Video Syrian Refugees Return to Tal Abyad

Syrian refugees in Turkey confirm they left their hometown of Tal Abyad because of intense fighting and coalition airstrikes, not because Kurdish fighters were engaged in ethnic cleansing, as some Turkish officials charged. VOA Kurdish Service reporter Zana Omer, in Tal Abyad, finds that civilians coming back to the town agree, as we hear in this report narrated by Roger Wilkison.
Video

Video Military Experts Question New Russian Tank Capabilities

Russia has been showing off its new tank design – the Armata T-14. Designers claim it is 20 years ahead of current Western designs - and driving it feels like playing a computer game. But military analysts question those assertions, and warn the cost could be too heavy a burden for Russia’s struggling economy. Henry Ridgwell reports.
Video

Video In Kenya, Police Said to Shoot First, Ask Questions Later

An organization that documents torture and extrajudicial killings says Kenyan police were responsible for 1,252 shooting deaths in five cities, including Nairobi, between 2009 and 2014, representing 67 percent of all gun deaths in the areas reviewed. Gabe Joselow has more from Nairobi.
Video

Video In Syrian Crisis, Social Media Offer Small Comforts

Za’atari, a makeshift city in Jordan, may be the only Syrian refugee camp to tweet its activities, in an effort to keep donors motivated as the war in Syria intensifies and the humanitarian crisis deepens. Inside the camp, families say mobile phone applications help hold together families that are physically torn apart. VOA’s Heather Murdock reports.
Video

Video Chemical-Sniffing Technology Fights Australia's Graffiti Vandals

Cities and towns all over the world spend huge amounts of resources battling graffiti writers who deface buildings, public transport vehicles and even monuments. Authorities in Sydney, Australia, hope a new chemical-sniffing technology finally will stop vandals from scribbling on walls in the passenger areas of commuter trains. VOA’s George Putic has more.
Video

Video Cambodia Struggling to Curb Child Labor

Earlier this year a United Nations report found 10 percent of Cambodian children aged 7-14 are working – one of the highest rates in the region – and said one in four children in that age bracket are forced to quit school to help their families. Although the child labor rate has dropped over the past decade, Cambodia has a lot more to do – including keeping more children in school. Robert Carmichael reports for VOA from Phnom Penh.

VOA Blogs